HGSI - Human Genome Sciences, Inc.

HGSI (Human Genome Sciences, Inc.)

• Entry price: $14
• Risk Level:  9
• Profit Potential: 9
• 1 yr Target Price: $25-$35

According to Yahoo Finance, Analysts estimate a 93.9% growth this year.

With substantial financial rights to certain products in GlaxoSmithKline, Amgen, Genentech and Roche’s line of drugs, all are major players in the clinical drug industry; HGS is a hot stock to buy.  Some of these drugs include darapladib(in Phase III development as a treatment for coronary heart disease) and Syncria (albiglutide)(in Phase III development as a treatment for type 2 diabetes).  Both of these drugs are promising and have high potential to send stock prices up.

Furthermore, HGS has a strategic agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of ZALBIN™ (formerly Albuferon®) which has completed Phase 3 development in chronic hepatitis C.  They are expecting to submit global marketing applications in fall 2009.

Another promising drug in the late stages of development is BENLYSTA™ (formerly LymphoStat-B®).  HGS successfully completed the initial Phase 3 trial treatment of systemic lupus and results of the second BENLYSTA Phase 3 trial are also expected in November 2009.

In the first half of 2009, HGS achieved its first product revenues of $162.7 million when they delivered raxibacumab (ABthrax(TM)) to the U.S. Strategic National Stockpile for the treatment of inhalation anthrax. In July 2009, HGS also secured a new purchase order for 45,000 doses of raxibacumab to be delivered to the U.S. Strategic National Stockpile over a three-year period.

Having one already commercialized drug, two in the process to be commercialized in fall 2009 and 2 high potential drugs in development make HGS a great short term buy.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.

Hot Stocks to Buy [Swine Flu Stocks]

Swine Flu Related Stocks - Which Swine Flu Stock is a hot buy?

• Risk Level : 10
• Profit Potential: 8
• Loss Possibility: 10

The swine flu outbreak is sweeping the world and it’s affecting everything from travel, energy hotels, sporting events and restuarants.  Pratically ever sector is affected by the swine flu outbreak.  This is something we did not expect and the market is starting to get affected by it’s outbreak.  As the overall market decline due to the swine flu outbreak, there is one sector that is actually doing well.  If you are a risk taker and would like to gamble on some hot stocks in the field of flu related vaccines, the following index will make for an attractive shorterm stock play.  We expect these swine flu related stocks to be hot for several weeks as the outbreak is only at it’s early stage. One stock we would like to make note of is AVII. In our opinion AVII did extremely well during the bird flu outbreak. AVII has not risen as much as the other RXFLU stocks and we see potential for it to double or triple it’s price in the short term. There is also a risk that it can lose half it’s value if the current influx of swine flu subsides. The RXFLU index compose of the following stocks.

Swine Flu Related stocks should be bought and sold with extreme caution.  It can rise 100% one day and fall 90% the next.  Becareful in your decision to buy or sell these stocks.

RMBS - Rambus Inc.

[RMBS] Rambus Incorporated - Hot Stocks to Buy Entry Price $9.75 - $10.75

• Risk level: 6
• Profit potential: 8
• Price Target: $20 - $22
• We expect RMBS to outperform in the near and long term

We are adding Rambus Incorporated (RMBS) to our Hot Stocks to Buy list and for good reasons.  On April 23, 2009 Rambus released their earnings with the following results:

• First quarter loss of $17.4 million (-.17 cents a share), Last year they had a loss of $14.4 million (-.14 cents a share).  Similar quarter last year the net loss was $15.5 million.
• Revenue was down 31 percent (-$27.3 million) from same quarter last year.

As dismal as the earnings report were, it came pretty much in line with what many analysts were expecting.

We see Rambus as an enconomy busting stock that will endure most of the turmoil expected in the world economy.  Being a safe harbor from the current state of the economy makes it a hot stock to buy.  While their continued battle with the three Amigo’s continue and verdict remains uncertain, we do see some positives for Rambus this coming year.

• The major positive is Microsoft’s expected release of their new Windows 7 operating system.  With the release of any new operating system from Microsoft, there is always an increase in new computer hardware purchase and with every new computer, RAM is required.
• Another positive from the Windows 7 release is the operating system is a 64 bit operating system.  64 bit operating systems can make use of more ram than the current 4gb constrained by 32 bit systems.  This will lead to increased RAM sales.
• The increased of online games and higher powered games will also help Rambus in their RAM sales.

We see a very bright future for Rambus this coming year and expect to see the stock double by year’s end.  Our entry price for this stock is between $9.75 - $10.75.  Our 12 month target price is $22.

As always we encourage you to do your own diligent research prior to making any purchase or sale of a stock.  Please read our disclaimers under “Terms” for more details.